PepGen(US:PEPG) Prnewswireยท2025-06-20 15:26Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors are reminded of the August 11, 2025 deadline to seek the role of lead plaintiff in the federal securities class action against PepGen [2][12]. - The law firm encourages anyone with information regarding PepGen's conduct to come forward, including whistleblowers and former employees [13]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - A clinical hold notice from the FDA on December 16, 2024, raised concerns about the CONNECT2 study, resulting in a 3.63% decline in stock price [7][8]. - Following updates on safety concerns and a voluntary pause of the CONNECT2 study, PepGen's stock fell by 21.74% on January 30, 2025, and by 18.86% on March 4, 2025 [9][10]. - On May 28, 2025, PepGen announced that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].